Ligand Pharmaceuticals LGND Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $274.48M+2.4% | $268.09M+6.7% | $251.23M+33.9% | $187.58M+3.4% | $181.49M+8.6% | ||
| $33.25M-59.0% | $81.18M-1.1% | $82.1M+23.0% | $66.75M+1.9% | $65.54M+206% | ||
| $94.48M+2.2% | $92.45M-0.6% | $93.03M+4.5% | $89.06M+3.0% | $86.5M+10.0% | ||
| $179.89M-20.8% | $227.09M-2.8% | $233.71M+5.3% | $221.85M-8.8% | $243.3M+28.2% | ||
| $94.59M+131% | $41M+134% | $17.52M+151% | -$34.27M+44.6% | -$61.81M-173% | ||
| 34.5%+19.2pp | 15.3%+8.3pp | 7%+25.2pp | -18.3%+15.8pp | -34.1%-20.5pp | ||
| $5.6M+18.7% | $4.72M+23.7% | $3.81M+4.6% | $3.64M-3.1% | $3.76M+23.9% | ||
| $18.54M+35.8% | $13.66M+48.5% | $9.2M+37.9% | $6.67M-14.6% | $7.81M-3.1% | ||
| $90.3M-23.5% | $117.96M— | —— | —— | —— | ||
| $16.24M— | $0+100% | -$102.55M+5.0% | -$107.94M+12.3% | -$123.14M— | ||
| $184.88M+16.3% | $158.96M— | —— | —— | —— | ||
| $31.32M-9.2% | $34.51M— | —— | —— | —— | ||
| $153.56M+23.4% | $124.45M+156% | $48.58M+164% | -$75.86M+42.8% | -$132.62M-3,189% | ||
| 55.9%+9.5pp | 46.4%+27.1pp | 19.3%+59.8pp | -40.4%+32.6pp | -73.1%-70.7pp | ||
| $7.43+26.1% | $5.89+190% | $2.03+150% | -$4.04+43.6% | -$7.16-3,480% | ||
| $7.90+24.2% | $6.36+175% | $2.31+157% | -$4.07+43.5% | -$7.20-5,438% | ||
| 80.7M+0.9% | 80M+2.6% | 78M+2.9% | 75.8M+2.6% | 73.9M+1.5% | ||
| 78.1M+0.9% | 77.4M+1.4% | 76.4M+1.5% | 75.2M+1.8% | 73.9M+2.0% | ||
| $32.55M-0.5% | $32.71M-0.5% | $32.87M-0.5% | $33.03M0.0% | $33.03M+0.2% | ||
| $12.97M-10.8% | $14.55M+1.1% | $14.39M+10.4% | $13.04M0.0% | $13.04M+17.8% | ||
| -$443K— | $0+100% | -$7.24M+54.4% | -$15.89M-8.7% | -$14.61M+2.9% | ||
| $41.44M-54.3% | $90.67M— | —— | —— | —— | ||
| —— | —— | -$8.28M+52.1% | -$17.31M+66.8% | -$52.2M-0.6% | ||
| $274.48M+2.4% | $268.09M+6.7% | $251.23M+33.9% | $187.58M+3.4% | $181.49M+8.6% | ||
| $94.59M+131% | $41M+134% | $17.52M+151% | -$34.27M+44.6% | -$61.81M-173% | ||
| $127.81M+70.9% | $74.78M+44.6% | $51.71M+7,892% | $647K+102% | -$26.57M-310% | ||
| $127.81M+70.9% | $74.78M+44.6% | $51.71M+7,892% | $647K+102% | -$26.57M-310% | ||
| 46.6%+18.7pp | 27.9%+7.3pp | 20.6%+20.2pp | 0.3%+15.0pp | -14.6%-22.2pp | ||
| $94.59M+131% | $41M+134% | $17.52M+151% | -$34.27M+44.6% | -$61.81M-173% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ligand Pharmaceuticals's profit margins?
- Gross margin is 91.9% and operating margin is 34.5%, with a 55.9% net margin.
- Where does Ligand Pharmaceuticals's income statement data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.